AU2001263217A1 - Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids - Google Patents

Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids

Info

Publication number
AU2001263217A1
AU2001263217A1 AU2001263217A AU6321701A AU2001263217A1 AU 2001263217 A1 AU2001263217 A1 AU 2001263217A1 AU 2001263217 A AU2001263217 A AU 2001263217A AU 6321701 A AU6321701 A AU 6321701A AU 2001263217 A1 AU2001263217 A1 AU 2001263217A1
Authority
AU
Australia
Prior art keywords
tetrahydrocannabinol
cell proliferation
delta8
methods
decreasing cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263217A
Other languages
English (en)
Inventor
Sumner Burstein
Lawrence Recht
Robert B. Zurier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001263217A1 publication Critical patent/AU2001263217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
AU2001263217A 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids Abandoned AU2001263217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60204935 2000-05-17
PCT/US2001/015927 WO2001087296A1 (fr) 2000-05-17 2001-05-17 Procedes pour reduire la proliferation cellulaire au moyen d'acides (3r, 4r)-delta8-tetrahydrocannabinol-11-oiques

Publications (1)

Publication Number Publication Date
AU2001263217A1 true AU2001263217A1 (en) 2001-11-26

Family

ID=22760084

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2001263217A Abandoned AU2001263217A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU6169501A Pending AU6169501A (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU6169501A Pending AU6169501A (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Country Status (13)

Country Link
US (2) US6448288B1 (fr)
EP (2) EP1307186A4 (fr)
JP (2) JP2003533478A (fr)
CN (2) CN1273123C (fr)
AT (1) ATE406156T1 (fr)
AU (5) AU2001263217A1 (fr)
CA (2) CA2409005A1 (fr)
DE (1) DE60135557D1 (fr)
HU (2) HUP0700038A2 (fr)
IL (3) IL152892A0 (fr)
NZ (2) NZ523028A (fr)
RU (2) RU2273476C2 (fr)
WO (3) WO2001087296A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509250B1 (fr) 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions de procedes et articles de fabrication destines a moduler la croissance osseuse
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065793A2 (fr) 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Traitement de la cystite interstitielle au moyen d'acides (6ar,10ar)-?8-tetrahydrocannabinol-11-oiques
WO2006065792A2 (fr) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Traitement de la cystite interstitielle au moyen d'analogues cannabinoides
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
ZA200802767B (en) 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (fr) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Utilisation antiemetique des acides (3r,4r)-δ8-tetrahydrocannabinol-11-oiques
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (fr) 2007-05-17 2008-11-27 California Pacific Medical Center Procédés et compositions pour traiter le cancer
MX2010006206A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2435080A2 (fr) 2009-05-29 2012-04-04 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
AU2001261695B2 (en) 2005-06-16
EP1307188A1 (fr) 2003-05-07
AU2001264680B2 (en) 2006-09-14
WO2001087295A8 (fr) 2003-04-10
US20040225011A1 (en) 2004-11-11
HUP0700038A2 (en) 2007-05-02
WO2001087296A1 (fr) 2001-11-22
IL152891A0 (en) 2003-06-24
WO2001087297A1 (fr) 2001-11-22
CA2409005A1 (fr) 2001-11-22
AU6468001A (en) 2001-11-26
CA2408961A1 (fr) 2001-11-22
HUP0700039A2 (en) 2007-05-02
IL152892A (en) 2010-06-30
JP2003533479A (ja) 2003-11-11
EP1307188B1 (fr) 2008-08-27
CN1227007C (zh) 2005-11-16
US6448288B1 (en) 2002-09-10
IL152892A0 (en) 2003-06-24
EP1307186A1 (fr) 2003-05-07
JP2003533478A (ja) 2003-11-11
EP1307186A4 (fr) 2005-10-19
CN1273123C (zh) 2006-09-06
AU6169501A (en) 2001-11-26
EP1307188A4 (fr) 2005-07-06
US6914072B2 (en) 2005-07-05
RU2272620C2 (ru) 2006-03-27
ATE406156T1 (de) 2008-09-15
WO2001087295A1 (fr) 2001-11-22
US20020022653A1 (en) 2002-02-21
RU2273476C2 (ru) 2006-04-10
NZ523029A (en) 2004-11-26
NZ523028A (en) 2004-09-24
CN1447685A (zh) 2003-10-08
DE60135557D1 (de) 2008-10-09
CN1452485A (zh) 2003-10-29

Similar Documents

Publication Publication Date Title
AU2001263217A1 (en) Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
WO2002053516A3 (fr) Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
AU2003237304A1 (en) Optical polarization beam combiner/splitter
AU2003213290A1 (en) Compound polarization beam splitters
AU2001273728A1 (en) Arrangement for connecting planar components
AU2001287156A1 (en) Treatment for high pressure bleeding
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2002353128A1 (en) Bracing system for stringed instrument
AU2002357003A1 (en) Indoles as naaladase inhibitors
WO2004022029A3 (fr) Compositions de soins personnels a base d'alcool ramifie
AU2003274615A1 (en) Using configuration identifiers for communicating configuration descriptions
AU2001283161A1 (en) Pumping arrangement for fiber amplifiers
AU2003216901A1 (en) Polarizing beamsplitter
AU2001269019A1 (en) Copolymers for optical data storage
AU2002235298A1 (en) Hydroformed running board
AU2002331595A1 (en) Novel vasoconstrictor cannabinoid analogs
AU2001288632A1 (en) N-way demultiplexer
HUP0304079A3 (en) Carcass alignment system for carcass splitter
AU2002351021A1 (en) Kit for reducing aching caused by pde-v inhibitors
AU3683700A (en) Database organization for increasing performance by splitting tables
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man
AU2002243647A1 (en) Novel mesogens
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator
AU2002250319A1 (en) Polarization combiner/splitter
AU2002315472A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors